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predictor of PWV in healthy subjects points to the relevance of 
HDL function in vascular physiology and arterial stiffness preven-
tion along life.
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Experimental and clinical observations have documented the role 
of the small GTPase Rac1 protein and cardiovascular diseases 
opening to the development of new potential pharmacological in-
tervention. In this study we characterized a new class of selective 
small molecule Rac inhibitors with the 3-aryl-1H-pyrazole-5-car-
boxamide nucleus. Starting from our previous identiication of Rac 
inhibitors (1), through a computational approach, 57 chemical enti-
ties were identiied and their Rac inhibitory eficacy evaluated by 
G-LISA assay. 23 compounds were found to reduce, Rac-GTP levels 
in cultured cells by more than 24.8%. A comparative analysis at 25 
μM was then performed and compounds 1, 2, 3, 11 and 21 resulted 
the most potent. Compounds 1, 2, 3 and 21 did not affect the activa-
tion of RhoA protein, while compound 11 partially reduced RhoA-
GTP levels. The IC50s for Rac inhibition of these compounds were 
between 2.9 and 29.1 μM and similar potencies were observed in 
a cell adhesion assay, a Rac1-dependent cellular event. From these 
analysis it was selected compound 2 as a most promising inhibitor 
to test in in-vitro and in-vivo models of atherosclerosis. Compound 
2 profoundly affected cytoskeleton organization of cultured human 
SMCs and inhibited SMC migration in response to PDGF-BB in a 
concentration dependent manner with an IC50 value of 5.8 µM. 
More interestingly, incubation of human monocytic cell line THP-1 
with Compound 2 (10 µM) completely abrogated their adhesion to 
cultured human umbilical endothelial cells (HUVEC) indicating a 
potent anti-inlammatory activity.
Taken together, in the present study we identiied a new selective 
small molecule Rac inhibitor capable to interfere with SMC migra-
tion and monocyte-endothelial cell adhesion, two pivotal features 
of atherogenesis. Further analysis will be carried out to test the 
effect of compound 2 on spontaneous atherosclerotic plaque de-
velopment in apoE-/- mice.
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Primary objective was to establish how lipid proile is modiied in 
patients affected by polygenic hypercholesterolemia after three 
and six weeks of therapy with Sterolip (a new nutriceutical product 
in bag containing 1.6 g of plant sterol) with respect to a placebo; 
secondary objectives were to verify the tolerability of the product, 
to test the long term eficacy after 12 weeks of treatment, to evalu-
ate the response to the therapy in relation with three genetic vari-
ants involved in sterol absorption.
Methods. We enrolled 60 patients over 18 years of age, affected 
by polygenic hypercholesterolemia in primary prevention with 
cardiovascular risk <20% in the next ten years. 30 patients were 
double-blind randomized with placebo and 30 patients with Ste-
rolip. The double blind treatment lasted six weeks at the end of 
which all patients were treated with Sterolip in open-label for other 
six weeks. Lipid proile was determined before treatment and ev-
ery three weeks. We genotyped all patients for APOE, NPC1L1 c. 
816C>G (L272L) and ABCG8 D19H polymorphisms. 
Results. The parameters that in the treatment group were sig-
niicantly reduced compared to the placebo group were total 
cholesterol (TC) and LDL Cholesterol (LDL-C) at three weeks of 
treatment (p<0.05). The product was good tolerated. Long term 
therapy is eficacious only in a few cases with a large interindivid-
ual variability. Carriers of G allele of NPC1L1 polimorphism have 
demonstrated a signiicant more consistent reduction of TC after 
three and six weeks of treatment in comparison to C allele carriers 
(p<0.05). 
Conclusions. In according with data published in literature this 
study demonstrated a clinically signiicant action of plant sterols af-
ter three weeks of treatment. In genetically predisposed individu-
als, the therapy may be considered for a more time. 
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Background. Nonalcoholic fatty liver disease (NAFLD), the most 
common chronic liver disease, encompasses a histological spec-
trum, ranging from simple steatosis (SS) to steatosis plus necro-
inlammation (nonalcoholic steatohepatitis, NASH), which can be 
differentiated only by liver biopsy. While SS has a benign hepato-
logical course, NASH can progress to end-stage liver disease. Ste-
rol regulatory element-binding factor (SREBF) genes code for key 
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nuclear transcription factors regulating lipid homeostasis: sterol 
regulatory element binding protein (SREBP)-1c regulates hepatic 
de novo lipogenesis and insulin sensitivity, while sterol regulatory 
element-binding factor-2 (SREBF-2) codes for SREBP-2, a mas-
ter transcriptional regulator of genes involved in cellular choles-
terol biosynthesis, uptake, and export. Therefore, SREBF-1c and 
SREBF-2 may modulate the genetic susceptibility to NAFLD and 
NASH. 
Objective. Factors predisposing to non-alcoholic fatty liver dis-
ease (NAFLD) and associated cardio-metabolic disorders are 
unknown. Sterol regulatory element-binding protein (SREBP)-
1c and SREBP-2, transcription factors regulating lipogenesis and 
cholesterol metabolism have been experimentally connected to 
NAFLD, but no human data exist. In population-based studies, 
single nucleotide polymorphisms (SNPs) in SREBF-1 gene have 
been connected to obesity, insulin resistance and T2DM, and the 
functional SNP rs133291 C/T in the SREBF2 gene has been linked 
to serum LDL-cholesterol, but there are no human data on the im-
pact of these SNPs on the risk of developing NAFLD and associ-
ated metabolic abnormalities. We hypothesized SREBF-1c/2 SNPs 
may not only predispose not only to NAFLD/NASH, but also affect 
NAFLD-associated cardio-metabolic risk. We aimed at:
1) prospectively assessing the role of SREBF-1c/2 SNPs in pro-
moting NAFLD development in apparently healthy subjects;
2) elucidating mechanisms connecting SREBF-1c/2 to liver in-
jury, glucose and lipid homeostasis in established NAFLD. 
Methods. We followed-up 165 non-obese nondiabetic participants 
in a population-based study, without NAFLD/metabolic syndrome, 
characterized for 2 common SREBF-1c and SREBF-2 polymor-
phisms, dietary habits, physical activity, adipokines, CRP, and 
endothelial dysfunction markers. NAFLD developers underwent 
an OGTT with Minimal Model analysis of glucose homeostasis 
parameters, and an oral fat tolerance test with measurement of 
plasma lipoproteins, adipocytes, and hepatocyte apoptosis marker 
cytokeratin-18 fragments. 
Results. After 7 years, 29% subjects developed NAFLD and 5% 
developed diabetes. SREBF-1c and SREBF-2 predicted incident 
NAFLD; SREBF-2 predicted non-alcoholic steatohepatitis (NASH), 
diabetes, CRP and endothelial dysfunction markers. In NAFLD, 
while SREBF-1c predicted histological steatosis and hepatic in-
sulin resistance, SREBF-2 predicted progressive liver histology, 
hepatic/muscle/adipose insulin resistance, pancreatic b-cell dys-
function, and an altered fat tolerance: higher postprandial lipemia, 
cholesterol enrichment of triglyceride-rich lipoproteins and ox-
LDLs, HDL-C reduction, adipokine imbalance (lower adiponectin 
and higher resistin), and higher cytokeratin-18 fragments. 
Conclusions. SREBF-2 predisposes to NASH and cardio-metabol-
ic disorders by affecting glucose homeostasis and dietary fat toler-
ance. We showed polymorphisms in genes coding for nuclear tran-
scription factor SREBP-2 predict incidence and severity of NAFLD 
and of associated abnormalities in glucose and lipid metabolism 
and in adipokine response to dietary fat. Our indings may have 
relevant implications: from a clinical standpoint, SREBF-1/2 SNPs 
may be used to select NAFLD patients at higher risk of develop-
ing progressive liver disease and cardio-metabolic complications 
for tight monitoring and experimental treatments. Furthermore, 
future research should verify whether a genetically-mediated mal-
adaptive response to a chronic, daily, repetitive stress like fat inges-
tion may link chronic overfeeding to obesity and its complications 
and to assess whether SREBP-2 pathway modulation may prevent 
cholesterol lipotoxicity in different tissues more effectively than 
currently available strategies, which selectively target hepatic cho-
lesterol synthesis or intestinal absorption.
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Introduction. Differences between small dense LDL (sd-LDL) 
proiles were evaluated in 108 probands with Familial Combined 
Hyperlipidemia (FCHL), 117 probands with Familial Hypercoles-
terolemia (FH) and 146 normolipidemic, normotensive, normo-
glicaemic healthy subjects among those consecutively admitted 
to the outpatient Lipid Clinic of the “Federico II” University of 
Naples. 
Methods. LDL particle separation was performed by Lipoprint 
System: 7 LDL subfractions (LDL 1 to LDL 7) were obtained, mean 
LDL particle size and LDL score (% of sd-LDL) were calculated. 
Results. LDL score was signiicantly (p<0.001) higher in FCHL 
patients as compared to FH patients (21.6±1.3 vs 15.3±1.0 mg/dL) 
and controls (3.3±5.0 mg/dL); mean LDL size was signiicantly 
lower (p<0.001) in FCHL patients than FH patients (262.8±0.5 
vs 264. ±0.4 Å) and controls (271.1±2.8 mg/dL). In a subsequent 
analysis we compared the amount of cholesterol in each LDL sub-
fractions of the two groups of patients and controls. LDL I and LDL 
II cholesterol were signiicantly (p<0.001) higher in FH patients 
as compared to FCHL patients (69.0±1.9 vs 44.4±1.9 mg/dL for 
LDL I) and controls (41.7±11.5 mg/dL); (69.5±2.0 vs 42.8±1.5 vs 
19.1±8.6 mg/dL for LDL II) (FH vs FCHL vs controls). 
Conclusions. These indings indicate that FCHL patients have 
LDL score signiicantly higher and mean LDL size signiicantly 
lower than FH patients and healthy subjects. Small, dense LDL 
particles have been associated with an increased risk of coronary 
artery disease. More studies are envisaged to investigate the spe-
ciic contribution of LDL subfractions to cardiovascular risk in FH 
patient. 
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Familial combined hyperlipidemia (FCHL) is a severe inherited 
hyperlipidemia with a high cardiovascular mortality. Affected in-
dividuals have elevated cholesterol or trygliceride concentrations 
or both. Such a lipid proile is frequently associated with an un-
favourable decrease in high density lipoprotein concentration, an 
elevated apolipoprotein B and an increased prevalence of athero-
genic, small, dense low-density lipoprotein (sd-LDL) subfractions. 
Family studies are necessary to establish the diagnosis of FCHL 
in each patient. 
Since it is not always possible to get some biochemical data from 
